Jason Hunt, MD
Division of Addiction Medicine
Department of Psychiatry
University of Florida
“Dr Hunt has disclosed that he has no relevant financial relationship(s). No one else in a position to control content has any financial relationships to disclose.”
Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. All relevant financial relationships have been mitigated.
Release Date: April 13, 2022
Expiration Date: April 13, 2025
Target Audience: All physicians
As a result of participation in this activity, participants should be able to:
- Explain the need for the use of medications in the treatment of opioid use disorder.
- State the main medications used for the treatment of opioid addiction and better understand how they are used.
- Describe the use of medications for the treatment of opioid addiction among special populations including pregnant women, adolescents, pain patients, and patients with co-occurring psychiatric illness.
- Identify the common misconceptions about using Suboxone to treat addiction (the myths of MAT).
Requirements for successful completion: Certificates are awarded upon successful completion (80% proficiency) of the post-test.
Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Resource(s) for further study:
- The Role of Science in Addressing the Opioid Crisis. Volkow, ND Collins, FS. N Engl J Med 2017; 377:391-394.
- A peek into opioid users’ brains as they try to quit. Lauren Neergaard, The Associated Press. Jul 13, 2019.
- ASAM. The Review Course in Addiction Medicine.
- Buprenorphine-Induced Changes in Mu-Opioid Receptor Availability in Male Heroin-Dependent Volunteers: A Preliminary Study. Zubieta et all [U Mich] Neuropsychopharmacology 23:326-334, 2000.
- 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial. Johan Kakko, Kerstin Dybrandt Svanborg, Mary Jeanne Kreek, Markus Heilig. 2003 Feb 22; 361 (9358): 662-8.
- Post-incarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System. Green TC, Clarke J, Brinkley-Rubinstein L. JAMA Psychiatry. 2018; 75(4):405-407.
- Kampman, K et al. (2015). The ASAM National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. Sep-Oct 2015;9(5):358-67.
- Association of frontal and posterior cortical gray matter volume with time to alcohol relapse: a prospective study. Rando K, Kwang-Ik H, Bhagwagar Z, Chiang-Shan R, Bergquist K, Guarnaccia J, Sinha R. Am J Psychiatry. 2011 Feb;168(2):183-92.
- Prelude to Passion: Limbic Activation by “Unseen” Drug and Sexual Cues. Childress, et al, PloS ONE 2008; 3(1): e1506.
- Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. McLellan et al. JAMA. 2000 Oct 4;284(13):1689-95.
- Analysis of Buprenorphine/Naloxone Dosing Impact on Treatment Duration, Resource Use and Costs in the Treatment of Opioid-Dependent Adults: A Retrospective Study of US Public and Private Health Care Claims. Khemiri A et al. Postgraduate Medicine. Vol. 126, 2014 – Issue 5. Pages 113-120. 13 Mar 2015.
- Loss of Dopamine Transporters in Methamphetamine Abusers Recovers with Protracted Abstinence. Volkow N, et al. Journal of Neuroscience, 1 December 2001, 21(23)9414-9418.
- TIP 63: Medications for Opioid Use Disorder. SAMHSA. July 2021. PEP21-02-01-002.
If you have any questions please feel free to contact Nancy Boyd at (352) 594-4298 or at firstname.lastname@example.org